Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05814666
Title Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)
Acronym PEMDA-HN
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Flamingo Therapeutics NV
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.